Osteoinductivity potential of rhBMP-2 associated with two carriers in different dosages |
| |
| Authors: | Priscilla Maria Fernandes Abdala Mamie Mizusaki Iyomasa Sandra Sato Maria Vitória Lopes Badra Bentley Dimitrius Leonardo Pitol Simone Cecílio Hallak Regalo Selma Siéssere João Paulo Mardegan Issa |
| |
| Institution: | 1.Department of Morphology, Oral Medicine and Physiology, Faculty of Dentistry,University of S?o Paulo,Ribeir?o Preto,Brazil;2.Department of Dental Materials and Prosthodontics, Faculty of Dentistry of Ribeir?o Preto,University of S?o Paulo,Ribeir?o Preto,Brazil;3.Faculdade de Ciências Farmacêuticas de Ribeir?o Preto,University of S?o Paulo,Ribeir?o Preto,Brazil |
| |
| Abstract: | The objective of this study was to evaluate bone formation after application of different doses of recombinant human bone
morphogenetic protein-2 (rhBMP-2) combined with monoolein or poloxamer gels, in critical bone defects of rats. Forty-five
Wistar rats were divided into nine treatment groups with five animals each: I: application of 1 μg rhBMP-2 + monoolein; II:
3 μg rhBMP-2 + monoolein; III: 7 μg rhBMP-2 + monoolein; IV: 1 μg rhBMP-2 + poloxamer; V: 3 μg rhBMP-2 + poloxamer; VI: 7 μg
rhBMP-2 + poloxamer; VII: monoolein only; VIII: poloxamer only; and IX: critical bone defect only. A critical-sized defect
of 6 mm diameter was produced in the left parietal bone and it was filled with gels of the above mentioned treatments. After
2 weeks, the calvarial bones were removed for histological processing. Bone formation in the groups that received poloxamer
gel and rhBMP-2 was not significantly different from the control group (IX). Groups receiving monoolein and rhBMP-2 (1 and
3 μg) and those that received only the carriers (VII and VIII) had less bone formation in relation to the control. The association
of rhBMP-2 to both poloxamer and monoolein did not exhibit any significant differentiation in bone formation in comparison
with the control group. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
